Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

Abstract Background The usage of immune checkpoint inhibitors (ICIs) is the standard practice for the treatment of metastatic melanoma. However, a significant amount of patients show no response to immunotherapy, while issues on its reliable response interpretation exist. Aim of this study was to in...

Full description

Bibliographic Details
Main Authors: Christos Sachpekidis, Annette Kopp-Schneider, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss
Format: Article
Language:English
Published: SpringerOpen 2021-09-01
Series:EJNMMI Research
Subjects:
Metastatic melanoma
Immunotherapy
18F-FDG PET/CT
Unconfirmed progressive disease
Pseudoprogression
Confirmed progressive disease
Online Access:https://doi.org/10.1186/s13550-021-00832-4

Internet

https://doi.org/10.1186/s13550-021-00832-4

Similar Items